Recent advances, challenges and updates on the development of therapeutics for malaria
EXCLI Journal · 06.05.2024 · 23 · 672-713
DOI: 10.17179/excli2023-6856 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift EXCLI Journal, online erschienen am 06.05.2024. Verfasst von Rimmy Nandal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shri Baba MastNath Institute of Pharmaceutical Sciences and Research, Baba Mast Nath University, Asthal Bohar, Rohtak-124001, Haryana, India. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Malaria has developed as a serious worldwide health issue as a result of the introduction of resistant Plasmodium species strains. Because of the common chemo resistance to most of the existing drugs on the market, it poses a severe health problem and significant obstacles in drug research. Malaria treatment has evolved during the last two decades in response to Plasmodium falciparum drug sensitivity and a return of the disease in tropical areas. Plasmodium falciparum is now highly resistant to the majority of antimalarial drugs. The parasite resistance drew focus to developing novel antimalarials to combat parasite resistance. The requirement for many novel antimalarial drugs in the future year necessitates adopting various drug development methodologies. Different innovative strategies for discovering antimalarial drugs are now being examined here. This review is primarily concerned with the description of newly synthesized antimalarial compounds, i.e. Tafenoquine, Cipargamin, Ferroquine, Artefenomel, DSM265, MMV390048 designed to improve the activity of pure antimalarial enantiomers. In this review, we selected the representative malarial drugs in clinical trials, classified them with detailed targets according to their action, discussed the relationship within the human trials, and generated a summative discussion with prospective expectations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Shri Baba MastNath Institute of Pharmaceutical Sciences and Research, Baba Mast Nath University, Asthal Bohar, Rohtak-124001, Haryana, India.
- College of Pharmacy, PGIMS University of Health Sciences, Rohtak-124001, Haryana, India.
- MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala 133207, India.
- Department of Pharmaceutical Sciences, Maharishi Dayanand University, Rohtak 124001 Haryana, India.
- Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi 110017, India.
- Department of Chemistry, Chaudhary Bansi Lal University, Bhiwani-127021, India.
Zitieren
APA
Nandal, R., Kumar, D., Aggarwal, N., Kumar, V., Narasimhan, B., Marwaha, R. K., Sharma, P. C., Kumar, S., Bansal, N., Chopra, H., & Deep, A. (2024). Recent advances, challenges and updates on the development of therapeutics for malaria. EXCLI Journal, 23, 672-713. https://doi.org/10.17179/excli2023-6856
Vancouver
Nandal R, Kumar D, Aggarwal N, Kumar V, Narasimhan B, Marwaha RK, et al. Recent advances, challenges and updates on the development of therapeutics for malaria. EXCLI Journal. 2024;23:672-713. doi:10.17179/excli2023-6856
BibTeX
@article{Nandal2024,
author = {Nandal, Rimmy and Kumar, Davinder and Aggarwal, Navidha and Kumar, Virender and Narasimhan, Balasubramanian and Marwaha, Rakesh Kumar and Sharma, Prabodh Chander and Kumar, Surender and Bansal, Nitin and Chopra, Hitesh and Deep, Aakash},
title = {Recent advances, challenges and updates on the development of therapeutics for malaria},
journal = {EXCLI Journal},
year = {2024},
volume = {23},
pages = {672--713},
doi = {10.17179/excli2023-6856}
}
EUVIMED